Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

A retrospective assessment of citalopram in children and adolescents with pervasive developmental disorders.

Couturier JL, Nicolson R.

J Child Adolesc Psychopharmacol. 2002 Fall;12(3):243-8.

PMID:
12427298
2.

The use of selective serotonin reuptake inhibitors in autism and related disorders.

Posey DJ, Erickson CA, Stigler KA, McDougle CJ.

J Child Adolesc Psychopharmacol. 2006 Feb-Apr;16(1-2):181-6. Review.

PMID:
16553538
3.

Pharmacotherapy to control behavioral symptoms in children with autism.

Doyle CA, McDougle CJ.

Expert Opin Pharmacother. 2012 Aug;13(11):1615-29. doi: 10.1517/14656566.2012.674110. Epub 2012 May 3. Review.

PMID:
22550944
4.

A retrospective chart review of risperidone use in treatment-resistant children and adolescents with psychiatric disorders.

Simeon J, Milin R, Walker S.

Prog Neuropsychopharmacol Biol Psychiatry. 2002 Feb;26(2):267-75. Review.

PMID:
11817503
5.

Selective serotonin reuptake inhibitors in autism: a review of efficacy and tolerability.

Kolevzon A, Mathewson KA, Hollander E.

J Clin Psychiatry. 2006 Mar;67(3):407-14. Review.

PMID:
16649827
6.

Atypical antipsychotics in children with pervasive developmental disorders.

Chavez B, Chavez-Brown M, Sopko MA Jr, Rey JA.

Paediatr Drugs. 2007;9(4):249-66. Review.

PMID:
17705564
7.

Pharmacological treatment options for autism spectrum disorders in children and adolescents.

Leskovec TJ, Rowles BM, Findling RL.

Harv Rev Psychiatry. 2008;16(2):97-112. doi: 10.1080/10673220802075852. Review.

PMID:
18415882
8.

Pharmacotherapy in children and adolescents with pervasive developmental disorders.

Scahill L, Koenig K.

J Child Adolesc Psychiatr Nurs. 1999 Jan-Mar;12(1):41-3. Review.

PMID:
10347430
9.
10.

Citalopram--a review of pharmacological and clinical effects.

Bezchlibnyk-Butler K, Aleksic I, Kennedy SH.

J Psychiatry Neurosci. 2000 May;25(3):241-54. Review.

11.

Diagnosis and evaluation of pervasive developmental disorders.

Scahill L.

J Clin Psychiatry. 2005;66 Suppl 10:19-25. Review.

12.

Pharmacotherapy of irritability in pervasive developmental disorders.

Stigler KA, McDougle CJ.

Child Adolesc Psychiatr Clin N Am. 2008 Oct;17(4):739-52, vii-viii. doi: 10.1016/j.chc.2008.06.002. Review.

PMID:
18775367
13.

[Efficacy and tolerability of escitalopram in anxiety disorders: a review].

Pelissolo A.

Encephale. 2008 Sep;34(4):400-8. doi: 10.1016/j.encep.2008.04.004. Epub 2008 Aug 15. Review. French.

PMID:
18922243
14.
15.

[Pharmacological treatments in patients with pervasive developmental disorders: A review].

Béhérec L, Quilici G, Rosier A, Gerardin P, Campion D, Guillin O.

Encephale. 2014 Apr;40(2):188-96. doi: 10.1016/j.encep.2012.01.014. Epub 2013 Dec 23. Review. French.

PMID:
24369879
16.

Autism and associated behavioral disorders: pharmacotherapeutic intervention.

Gilman JT, Tuchman RF.

Ann Pharmacother. 1995 Jan;29(1):47-56. Review.

PMID:
7711345
17.

Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD).

Williams K, Wheeler DM, Silove N, Hazell P.

Cochrane Database Syst Rev. 2010 Aug 4;(8):CD004677. doi: 10.1002/14651858.CD004677.pub2. Review. Update in: Cochrane Database Syst Rev. 2013;8:CD004677.

PMID:
20687077
18.

Psychopharmacological treatment of non-comorbid and comorbid pervasive developmental disorder and pediatric bipolar disorder.

Hamrin V, McDonnell MA, Moffett J, Durso S.

Minerva Pediatr. 2008 Feb;60(1):87-101. Review.

PMID:
18277368
19.

[Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents].

Purper-Ouakil D, Fourneret P, Wohl M, Rénéric JP.

Encephale. 2005 May-Jun;31(3):337-48. Review. French.

PMID:
16142049
20.

The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders.

Posey DJ, McDougle CJ.

Harv Rev Psychiatry. 2000 Jul-Aug;8(2):45-63. Review.

PMID:
10902094

Supplemental Content

Support Center